Dynamic skeletal muscle deterioration predicts poorer survival in hepatocellular carcinoma: a systematic review and meta-analysis

Dynamic skeletal muscle deterioration during hepatocellular carcinoma (HCC) treatment may capture changes in host vulnerability during treatment. Yet the available evidence is fragmented across treatment settings, imaging metrics, and definitions of muscle loss, and the magnitude of the prognostic association remains uncertain. We aimed to synthesise the evidence and quantify the association between dynamic skeletal muscle deterioration and overall survival (OS) in patients with HCC. We systematically reviewed prognostic factor studies reporting serial imaging-derived skeletal muscle measurements and adjusted Cox model estimates for OS. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Heterogeneity was quantified with the I² statistic and 95% prediction intervals. Prespecified sensitivity analyses and exploratory random-effects meta-regression examined robustness and potential effect modification by treatment type and muscle metric. Fourteen retrospective cohorts comprising 2,844 patients were included, of whom 2,549 contributed to the extracted Cox models. Dynamic skeletal muscle deterioration was significantly associated with poorer OS (random-effects HR 2.28, 95% CI 1.72–3.01; I² = 56%), with a 95% prediction interval of 1.15–4.50. The association remained directionally consistent across all prespecified sensitivity analyses. Exploratory meta-regression did not detect statistically significant differences by treatment modality or muscle metric, but precision was limited. Certainty of evidence was low because of risk of bias, heterogeneity and possible small-study effects. Dynamic skeletal muscle deterioration was associated with an approximately twofold higher hazard of death in HCC and represents a candidate prognostic biomarker requiring prospective validation. Whether serial muscle assessment improves prediction or clinical decision-making remains to be established. The current evidence does not demonstrate that preventing muscle loss improves survival.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2026-10-24
DOI
https://doi.org/10.1186/s12885-026-17242-1
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dynamic skeletal muscle deterioration predicts poorer survival in hepatocellular carcinoma: a systematic review and meta-analysis

Dianzhe Tian, 杜顺达, Hong Zhao, Fengdan Wang et al.
BMC Cancer
Hepatocellular Carcinoma Treatment and Prognosis
article

Dynamic skeletal muscle deterioration predicts poorer survival in hepatocellular carcinoma: a systematic review and meta-analysis

Dianzhe Tian, 杜顺达, Hong Zhao, Fengdan Wang, 徐意瑶, Xin Lü, Zuyi Yang, Zixuan Hu, Yaoge Liu, Shaoqing Zhu, Xinshi Li, Shengzhi Liu, Lei Zhang
article en

Abstract

Dynamic skeletal muscle deterioration during hepatocellular carcinoma (HCC) treatment may capture changes in host vulnerability during treatment. Yet the available evidence is fragmented across treatment settings, imaging metrics, and definitions of muscle loss, and the magnitude of the prognostic association remains uncertain. We aimed to synthesise the evidence and quantify the association between dynamic skeletal muscle deterioration and overall survival (OS) in patients with HCC. We systematically reviewed prognostic factor studies reporting serial imaging-derived skeletal muscle measurements and adjusted Cox model estimates for OS. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Heterogeneity was quantified with the I² statistic and 95% prediction intervals. Prespecified sensitivity analyses and exploratory random-effects meta-regression examined robustness and potential effect modification by treatment type and muscle metric. Fourteen retrospective cohorts comprising 2,844 patients were included, of whom 2,549 contributed to the extracted Cox models. Dynamic skeletal muscle deterioration was significantly associated with poorer OS (random-effects HR 2.28, 95% CI 1.72–3.01; I² = 56%), with a 95% prediction interval of 1.15–4.50. The association remained directionally consistent across all prespecified sensitivity analyses. Exploratory meta-regression did not detect statistically significant differences by treatment modality or muscle metric, but precision was limited. Certainty of evidence was low because of risk of bias, heterogeneity and possible small-study effects. Dynamic skeletal muscle deterioration was associated with an approximately twofold higher hazard of death in HCC and represents a candidate prognostic biomarker requiring prospective validation. Whether serial muscle assessment improves prediction or clinical decision-making remains to be established. The current evidence does not demonstrate that preventing muscle loss improves survival.

BMC Cancer
Capital Medical University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking Union Medical College Hospital (CN)
Openalex Percentile: Top 15%
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon